ClinicalTrials.gov confirms that this Phase 3 study is registered and currently listed as Active Not Recruiting. This establishes the study's existence and registry-reported design/status, not a treatment benefit.
In a small, phase 1, first-in-human trial, a personalized cancer vaccine built from each patient's own tumor mutations was given after surgery to patients with high-risk kidney cancer. All 9…
In a small, phase 1, first-in-human trial, a personalized cancer vaccine built from each patient's own tumor mutations was given after surgery to patients with high-risk kidney cancer. All 9…
✓ Primary source cited
Last reviewed
Clinical Trials
Important: Eligibility and enrollment are not guaranteed, and listing here is not a treatment recommendation. Talk to your care team.
Adults with high-risk, fully surgically resected clear cell renal cell carcinoma (stage III or IV, no remaining visible cancer after surgery), given a personalized neoantigen vaccine with or without ipilimumab in the adjuvant (post-surgery, preventive) setting, in a phase 1, first-in-human trial.
Last reviewed
2026-08-13
Regulatory status by jurisdiction
Unspecified jurisdiction
Status
Investigational
Last verified
2026-08-13
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.